Klausner Richard 4
4 · Lyell Immunopharma, Inc. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
Klausner Richard
Director
Transactions
- Conversion
Common Stock
2021-06-21+3,765,842→ 3,765,842 total(indirect: By LLC) - Conversion
Series A Convertible Preferred Stock
2021-06-21−3,765,842→ 0 total(indirect: By LLC)→ Common Stock (3,765,842 underlying)
Holdings
- 2,967,834
Common Stock
Footnotes (2)
- [F1]The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.
- [F2]The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein